Navigation Links
Peter Baumann named Howard Hughes Medical Institute Early Career Scientist
Date:3/26/2009

rated shortening have been linked to several degenerative diseases. On the other hand, telomerase, a protein central to telomere elongation, is activated in most cancer cells and is considered a promising target for anticancer drugs. By understanding how telomere lengthening is regulated and how telomeres are prevented from becoming too short, Dr. Baumann's research team hopes to lay the foundation for the development of treatments for cancer as well as degenerative syndromes such as dyskeratosis congenita and aplastic anemia.

Dr. Baumann leads an eight-person team at the Stowers Institute composed of postdoctoral researchers, graduate students, and scientific staff. Dr. Baumann's laboratory has published ten papers in peer-reviewed journals, including four papers of remarkable influence in the field of chromosome dynamics in the last two years.

"This support from HHMI creates a fantastic opportunity for us to expand our research into new areas while at the same time building on our findings from the past few years," said Dr. Baumann.

"Peter Baumann's HHMI appointment is a significant landmark in his successful career as a laboratory leader, and it is a source of pride for the Stowers Institute," said William B. Neaves, Ph.D., President and CEO. "Selection by the HHMI after rigorous, comprehensive review represents an enormous vote of confidence in a biomedical scientist, and all of us at the Institute are delighted that Dr. Baumann will have the additional resources provided by this appointment to accelerate his innovative research."

Kevin Eggan, Ph.D., Assistant Investigator with the Stowers Medical Institute (SMI), also was named an Early Career Scientist by HHMI. SMI was established in 2005 in Cambridge, Massachusetts by Jim and Virginia Stowers.

Dr. Baumann also holds an appointment as Assistant Professor in the Department of Molecular and Integrative Physiology at The University of Kansas School of Medicine.
'/>"/>

Contact: Marie Jennings
mfj@stowers.org
816-926-4015
Stowers Institute for Medical Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Harold Mooney and Peter Raven, winners of the BBVA Foundation Award for Conservation Biology
2. UM coral scientist Peter Glynn wins award for scholarly activity
3. Peter J. McGuire, MB BCh, is awarded the 2008-2009 Genzyme/ACMGF Clinical Genetics Fellowship
4. Wildlife biologist named Roger Tory Peterson Medal recipient, speaker
5. Whitehead member Peter Reddien named HHMI Early Career Scientist
6. Baumann lab identifies elusive telomere RNA subunit in single cell model
7. Stowers Institutes Baumann Lab identifies key step in maturation pathway of telomerase
8. CIC Again Named to Software Magazines Annual Prestigious Software 500 List
9. UD named a regional research participant in National Children’s Study
10. PNNLs Richard Smith named to prestigious Scientific American 50 list of outstanding leaders
11. NJIT start-up company NeuroTrax named best in show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... for prostate cancer in men may get a second life ... common form of cancer in women worldwide, scientists are reporting ... Chemistry . Chien Chou and colleagues say that the ... potential biomarker of breast cancer in women. However, levels of ...
... were to escape from captivity they could succeed in ... researchers have found. Their research, published in Evolutionary ... salmon as they are considered for commercial farming. ... been of interest to the aquaculture industry and now ...
... German . Plants, too, have an immune system ... and the subsequent immune response, in particular at the cell ... cause plant diseases have their weapons, too. Some are able ... particularly ingenious attacker, powdery mildew, can even reprogram cells in ...
Cached Biology News:First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool 2TUM researchers discover a new switch in resistance to plant diseases 2
(Date:5/22/2015)... 22, 2015  Actavis plc (NYSE: ACT ) ... of Appeals for the Second Circuit has issued a ... the Company to continue distribution of NAMENDA ® ... http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   "While we are disappointed ... intend to continue our strong efforts to convey the ...
(Date:5/21/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... and commercializes proprietary technologies and products for advanced microarray ... the second fiscal quarter ended March 31, 2015. ... advance business with our existing customers and to develop ... CEO of SQI. "The delivery of a fully automated ...
(Date:5/21/2015)... 21, 2015 uBiome, the leading ... partnership with PicnicHealth, a healthcare company that collects ... with Inflammatory Bowel Disease (IBD) will receive a ... uBiome research kit. Both companies were funded by ... , For more information on this partnership and ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
Breaking Biology Technology:Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today ... 1 safety study of Sangamo,s zinc finger nuclease (ZFN) based ... the internet. , Data were presented in a student course ... single subject treated with SB-728-T who, as part of the ...
... Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... development company that identifies and advances a diverse portfolio ... announced that results from a study evaluating nimotuzumab were ... Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. ...
... , BALTIMORE, Nov. 18 Champions Biotechnology, ... development company with a predictive preclinical platform aimed at ... drugs, has established an exclusive licensing agreement with Yale ... Bithionol for cancer treatment. Scientists from Yale and ...
Cached Biology Technology:Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 4
... NAP-10 Columns, 50. For rapid and ... 10-mers) in less than 15 minutes by ... in distilled water containing 0.15% Kathon CG/ICP ... volume: 0.5 ml (NAP-5), 1 ml ...
Human Serpin A3 MAb (Clone 213907)...
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Mouse Semaphorin 6B MAb (Clone 256537)...
Biology Products: